Cymabay Therapeutics
CBAY
CBAY was delisted on the 21st of March, 2024.
29 hedge funds and large institutions have $18.2M invested in Cymabay Therapeutics in 2015 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 4 increasing their positions, 8 reducing their positions, and 8 closing their positions.
13% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 8
4% more funds holding
Funds holding: 28 → 29 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
50% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 8
68% less capital invested
Capital invested by funds: $56.7M → $18.2M (-$38.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVI
Pura Vida Investments
New York
|
+$821K |
| 2 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$190K |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$155K |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
+$103K |
| 5 |
JP Morgan Chase
New York
|
+$103K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
-$2.34M |
| 2 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
-$1.36M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.09M |
| 4 |
IHM
Iguana Healthcare Management
New York
|
-$1.07M |
| 5 |
VAM
Visium Asset Management
New York
|
-$833K |
CBAY Hedge Fund Activity: Q2 2015 in Review
29 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q2 2015, worth a combined $18.2M — down 68% from $56.7M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new CBAY positions and 8 closed out — a net gain of 1 holder — while 4 added to existing stakes and 8 trimmed.
The largest buyer was Pura Vida Investments, opening a new position worth an estimated $821K. The largest seller was Lombard Odier Asset Management (USA), cutting an estimated $2.34M.
- 29 institutional investors held Cymabay Therapeutics (CBAY) as of Q2 2015, up from 28 in Q1 2015.
- Funds reported $18.2M of Cymabay Therapeutics stock for Q2 2015, down 68% quarter-over-quarter.
- 9 funds opened new Cymabay Therapeutics positions in Q2 2015 and 8 closed out, a net change of +1 holder.
- The largest Cymabay Therapeutics buyer in Q2 2015 was Pura Vida Investments, an estimated $821K added.
- The largest Cymabay Therapeutics seller in Q2 2015 was Lombard Odier Asset Management (USA), an estimated $2.34M sold.
Based on aggregated 13F filings for Q2 2015.